GoldenGolden
StemoniX

StemoniX

StemoniX is a biotechnology company accelerating drug discovery through creating pluripotent stem cell-derived cardiac and neuronal platforms.

No article has been written about this topic yet.
Paste a URL about this topic to auto-extract knowledge.
Visit our Writing Guide for help on how to write about a topic,
and check out an example of a well filled out topic page.

No article has been written about this topic yet.
Be the first one to add some text.

Loading AI-assisted edit mode...

Timeline

March 2019
StemoniX raises a $14,400,000 series B round from Alumni Ventures Group, Brightstone Venture Capital, Crescent Ridge Partners, Keshif Ventures, Mayo Clinic and Seed San Diego.
2014
StemoniX was founded.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
StemoniX Inc funding round, March 2019
14,400,000
March 2019
3 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

StemoniX® Secures $14.4 Million to Accelerate Commercialization of microOrgan® Drug Discovery Platforms

StemoniX

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
BioSpace
April 5, 2021
BioSpace
Vyant Bio, Inc. (the "Company") (Nasdaq: VYNT), is a new force in drug discovery, focused on integrating human-powered scientific and technology-based systems to de-risk and accelerate the discovery of therapeutics for biopharma partners as well as for the proprietary pipeline of the Company.
Jonathan Shieber
August 11, 2020
TechCrunch
With a slew of partnerships with large pharmaceutical companies under its belt and the successful spin out of at least one new company, Atomwise has already proved the value of its machine learning platform for discovering and commercializing potential small molecule therapies for a host of conditions. Now the company has raised $123 million in [...]
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.